April 7, 2015 | Medical equipment giant Medtronic has invested $2 million in DreaMed Diabetes, an Israeli startup company that develops a new delivery system of insulin. DreaMed has signed an exclusive development and license agreement with Medtronic for the development and marketing of products incorporating DreaMed’s technology in Medtronic’s insulin pumps. DreaMed was founded in 2014 by Eran Atlas and Shahar Miller.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments